Vinblastine

Vinblastine
Clinical data
Trade names	Velban, Velbe, others
Other names	VBL, vincaleukoblastine
AHFS/Drugs.com	Monograph
MedlinePlus	a682848
License data	US DailyMed: Vinblastine;
Pregnancy; category	AU: D;
Routes of; administration	intravenous
ATC code	L01CA01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	n/a
Metabolism	Liver (CYP3A4-mediated)
Elimination half-life	24.8 hours (terminal)
Excretion	Bile duct and kidney
Identifiers
	IUPAC name dimethyl (2β,3β,4β,5α,12β,19α)-15-[(5S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol- 9-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3,4-dicarboxylate;
CAS Number	865-21-4 ;
PubChem CID	241903;
DrugBank	DB00570 ;
ChemSpider	211446 ;
UNII	5V9KLZ54CY;
KEGG	D08675 ;
ChEBI	CHEBI:27375 ;
ChEMBL	ChEMBL159 ;
NIAID ChemDB	002673;
CompTox Dashboard (EPA)	DTXSID8021430 ;
ECHA InfoCard	100.011.577
Chemical and physical data
Formula	C46H58N4O9
Molar mass	810.989 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [H][C@]89CN(CCc1c([nH]c2ccccc12)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@@]5([H])[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]7(CC)C=CCN6CC[C@]45[C@@]67[H])C8)C[C@](O)(CC)C9;
	InChI InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1 ; Key:JXLYSJRDGCGARV-XQKSVPLYSA-N ;
	(what is this?) (verify)

Vinblastine, sold under the brand name Velban among others, is a chemotherapy medication, typically used with other medications, to treat a number of types of cancer.^[2] This includes Hodgkin's lymphoma, non-small-cell lung cancer, bladder cancer, brain cancer, melanoma, and testicular cancer.^[2] It is given by injection into a vein.^[2]

Most people experience some side effects.^[2] Commonly it causes a change in sensation, constipation, weakness, loss of appetite, and headaches.^[2] Severe side effects include low blood cell counts and shortness of breath.^[2] It should not be given to people who have a current bacterial infection.^[2] Use during pregnancy will likely harm the baby.^[2] Vinblastine works by blocking cell division.^[2]

Vinblastine was isolated in 1958.^[3] An example of a natural herbal remedy that has since been developed into a conventional medicine, vinblastine was originally obtained from the Madagascar periwinkle.^[4] It is on the World Health Organization's List of Essential Medicines.^[5]

^ "Velbe Product information". Health Canada. 2 October 2000. Retrieved 16 February 2025.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Vinblastine Sulfate". The American Society of Health-System Pharmacists. Archived from the original on 2 January 2015. Retrieved 2 January 2015.
^ Ravina E (2011). The evolution of drug discovery : from traditional medicines to modern drugs (1. Aufl. ed.). Weinheim: Wiley-VCH. p. 157. ISBN 9783527326693. Archived from the original on 1 August 2017.
^ Liljefors T, Krogsgaard-Larsen P, Madsen U (2002). Textbook of Drug Design and Discovery (Third ed.). CRC Press. p. 550. ISBN 9780415282888. Archived from the original on 20 December 2016.
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[1] "Velbe Product information". Health Canada. 2 October 2000. Retrieved 16 February 2025.

[AHFS2015-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Vinblastine Sulfate". The American Society of Health-System Pharmacists. Archived from the original on 2 January 2015. Retrieved 2 January 2015.

[Ravina_2011-3] Ravina E (2011). The evolution of drug discovery : from traditional medicines to modern drugs (1. Aufl. ed.). Weinheim: Wiley-VCH. p. 157. ISBN 9783527326693. Archived from the original on 1 August 2017.

[4] Liljefors T, Krogsgaard-Larsen P, Madsen U (2002). Textbook of Drug Design and Discovery (Third ed.). CRC Press. p. 550. ISBN 9780415282888. Archived from the original on 20 December 2016.

[WHO23rd-5] World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[1]

[2]

[3]

[4]

[5]